Bone marrow stem cells are involved in liver repair in mice

Li Changzhu,Liang Guangping,Tang Xudong,Wu Yuyun,Wang Sumin,Zhao Jingjing,Fang Dianchun,Yang Shiming

DOI: https://doi.org/10.16016/j.1000-5404.2011.09.007

2011-01-01

Abstract:Objective To investigate the feasibility of bone marrow derived stem cells(bone marrow stem cells,BMSCs) differentiate into hepatocytes in vivo,in order to provide the theoretical basis for BMSCs participating in the repair of injuring liver.Methods After 30 female C57BL/6 mice received a whole body radiation of 10 Gy 60Co,they were given bone marrow transplantation from the same strain male mice immediately.In 21 d after transplantation,these female mice received an intraperitoneal injection of carbon tetrachloride(CCl4) to induce liver injury.Then their livers were removed for double fluorescence labeling of Y chromosome by FISH and albumin(ALB) by immunofluorescence at the 2nd,3rd,4th,7th,14th,21st and 28th d after CCl4 injection,which will indicate whether the BMSCs were differentiated to hepatocytes.Meanwhile,the liver content of several associated factors,such as stromal cell-derived factor1(SDF-1) and its receptor CXCR-4,hepatocyte growth factor(HGF) and stem cell factor(SCF) were also detected by ELISA.Results Double positive cells,which co-expressed Y chromosome by FISH and Alb by immunofluorescence,were found from 2 to 28 d after after CCl4 injury at a positive rate of 3.763% to 5.578%.Meanwhile,ELISA indicated that the liver contents of SDF-1,CXCR-4,SCF and HGF were increased gradually after injury with CCl4 and reached the peak at the 21st day after CCl4 injury(P<0.05,compared with those at other time points),which was consistent with the counting of double positive cells by FISH and immunofluorescence.Conclusion BMSCs may directly differentiate to live cells in vivo and/or indirectly promote original liver stem cells proliferation and differentiation by secreting cellular factors,and thus be involved in the repair of injuring liver.These results provide the evidence for BMSCs in the treatment of end stage liver disease.